CVS Health has announced the addition of four new members to its board of directors, a move that includes the CEO of a hedge fund known for its critical stance towards the company, which has faced significant challenges lately.

On Monday, the organization revealed that it has increased the size of its board to 16 members after having “productive discussions” with Glenview Capital Management, a shareholder that holds around 1% of CVS’s shares, as reported by the data firm FactSet.

Glenview has publicly stated that CVS Health is not meeting its full potential, especially as the company has revised its earnings forecasts downwards multiple times this year. As part of the new appointments, Glenview CEO Larry Robbins will join the CVS Health board, alongside Guy Sansone, the CEO and Chairman of H2 Health, Doug Shulman, who is the Chairman of OneMain Holdings, and Leslie Norwalk, a former acting administrator for the Centers for Medicare and Medicaid Services.

According to CVS Health’s Executive Chairman Roger Farah, these new board members are expected to bring fresh perspectives along with extensive experience in the market and industry, aimed at enhancing the company’s financial and operational outcomes.

Analyst Michael Cherny from Leerink Partners noted that the board expansion aligns with Glenview’s investment and vocal comments regarding the company, while also suggesting that these moves do not drastically shift the direction in which CVS was already intending to progress.

CVS Health, headquartered in Woonsocket, Rhode Island, operates one of the largest drugstore chains in the United States and boasts a significant pharmacy benefit management wing which manages prescription drug plans for various stakeholders. The firm also serves nearly 27 million individuals through its Aetna insurance segment.

In recent times, CVS Health has concentrated on revitalizing its struggling insurance operations, a key factor affecting its overall performance for a number of quarters. Additionally, the company is experiencing new leadership dynamics, with David Joyner, a veteran within the organization, taking over the CEO position from Karen Lynch last month.

After a challenging year that has seen its stock price decline, shares of CVS Health saw an increase of over 3%, reaching $54.96 during morning trading on Monday.